Xalacom is the first fixed combination PG eyedrops launched on the market in the world by Pfizer. Treatment of glaucoma with fixed combination eye drops is a new trend of medication at home and abroad. Essex Medipharma is responsible for the promotion and sale of the product in the mainland China.
Pharmacological action: The product contains two active ingredients - latanoprost and timolol maleate. They reduce increased intraocular pressure (IOP) by different mechanisms. In comparison with independent medication of each ingredient, the combination of the two ingredients can produce a synergistic effect and extra effect of IOP reduction can be achieved. Latanoprost is an analogue of prostaglandin F2α, which is a selective prostaglandin FP receptor agonist that can reduce IOP by enhancing the outflow of aqueous humor. Timolol is a nonselectiveβ-1andβ-2 adrenocepter blocker without obvious sympathetic activity and it has no direct effect on myocardial inhibition or membrane stability either. Timolol can reduce IOP by decreasing the aqueous humor generated by ciliary epithelial cell. Its definite action mechanism is not clear yet. Perhaps it works by restraining the synthesis of CaMP activated by endogenous β-epinephrine.
Two mechanisms work complementarily for the reduction of IOP, powerful efficacy achieved；
One drop per day, little damage to ocular surface；
A fixed combination product recommended by the guidelines as an optimized option for combination treatment of glaucoma.
The product is indicated for the reduction of elevated IOP of patients with open-angle glaucoma and ocular hypertension. It is applicable for patients with poor efficacy from local treatment with β-receptor blocker.